Daniel J. Moore

Dan Moore became President and Chief Executive Officer of Cyberonics in May 2007.  During the first three years of his tenure, the Company resumed meaningful epilepsy revenue growth and returned to profitability after multiple years of losses.  Net sales for fiscal year 2010 were $167.8 million resulting in income from operations of $36.9 million.  Under the direction of Mr. Moore and his senior management team, Cyberonics is focused on introducing medical devices and expanding Vagus Nerve Stimulation (VNS) Therapy® franchise for patients suffering from epilepsy.  

Cyberonics has approximately 500 employees world-wide, with more than 430 in the U.S. Cyberonics’ stock is traded on the NASDAQ stock exchange under the symbol CYBX.

Mr. Moore joined Cyberonics from Boston Scientific where, since 1989, he held positions in sales, marketing and senior management in the United States and in Europe.  In his last position at Boston Scientific, he was President, International Distributor Management.  Prior to this, he was President, Inter-Continental, the fourth largest business unit of Boston Scientific with more than 1,000 global employees and revenues exceeding $700 million.  Mr. Moore began his career with Procter and Gamble after graduating from Harvard College.  He also earned an MBA from Boston University.

Mr. Moore serves on the board of directors for Smiling Kids, Inc., Epilepsy Foundation of America, Epilepsy Foundation of Texas Houston/Dallas/Fort Worth, BioHouston, Inc., and MDMA.  He is also a member of the Purdue University Weldon School of Biomedical Engineering Advisory Board.